All In Biotech

Drug Trial Radar · NCT01966107

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD (ASCENT COPD)

Last checked: Nov 19, 2026Latest source record: Dec 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 3,635 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,635

Actual

Start

Oct 16, 2013

Primary completion

Sep 21, 2017

Study completion Sep 21, 2017

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 21, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Objectives of this study are to assess the safety of Aclidinium bromide on major adverse cardiovascular events (MACE), to assess the overall safety of Aclidinium bromide and to assess whether Aclidinium bromide reduces moderate or severe COPD exacerbations. This study is a double-blind, randomized, placebo controlled, parallel-group study to evaluate the effect of Aclidinium bromide on the cardiovascular safety and COPD exacerbations in patients with moderate to very severe COPD, as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.

Conditions

  • COPD
  • Chronic Obstructive Pulmonary Disease
  • Moderate to Very Severe COPD

Interventions

  • Aclidinium BromideDrug

    400 μg, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)

  • PlaceboDrug

    Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Subject Per Year During the First Year of TreatmentTime frame: 12 months
  2. Number of Participants With Major Adverse Cardiovascular Event (MACE) - on Study AnalysisTime frame: At Screening, Treatment period (upto 36 months) and Post-treatment follow-up (PTFU)

Locations

468 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Florence, Alabama

  • Research Site

    Foley, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Jasper, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Tuscaloosa, Alabama

  • Research Site

    Chandler, Arizona

  • Research Site

    Glendale, Arizona

  • Research Site

    Mesa, Arizona

  • Research Site

    Peoria, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Hot Springs, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Bakersfield, California

  • Research Site

    Encinitas, California

  • Research Site

    Escondido, California

  • Research Site

    Fresno, California

  • Research Site

    Gold River, California

  • Research Site

    Huntington Beach, California

  • Research Site

    La Mirada, California

  • Research Site

    Laguna Hills, California

  • Research Site

    Lincoln, California

  • Research Site

    Loma Linda, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

Showing 40 of 468 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.